CytomX Therapeutics, Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$76M
R&D
$69M
D&A
$1M
Operating Income
$-22M
EBITDA
$-21M
Interest Expense
—
Interest Income
$5M
Other Income/Expense
$28K
Pretax Income
$-17M
Tax Provision
$238K
Net Income
$-17M
Operating Margin
-29.3%
Net Margin
-22.8%
Effective Tax Rate
-1.4%
Deferred Tax Assets
$932K
Deferred Tax Liabilities
$0
DTA Valuation Allowance
$187M
Tax Credit Carryforwards
$24M
NOL Carryforwards
$85M
ETR (Continuing Operations)
-1.4%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
-1.4%
Operating Lease Cost
$5M
Revenue YoY Variation
-44.8%
Income YoY Variation
-189.5%